진양제약
Financials
Valuation Metrics
진양제약's Market Cap is ₩557B. At end of 2025 it was ₩711B. Ranked #1705 of 2,421 in KR market (top 70%), #1031 of 1,640 on KOSDAQ (top 63%), #182 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 79%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 55.69B KRW | KR#1,705/2,421 Sec#182/231 |
| Revenue | 124.61B KRW | KR#1,289/2,421 Sec#79/231 |
| Net Income | 22.80B KRW | KR#658/2,421 Sec#44/231 |
| Total Assets | 274.42B KRW | KR#1,086/2,421 Sec#73/231 |
| Net Assets | 162.16B KRW | KR#1,086/2,421 Sec#76/231 |
| Employees | 213 | KR#1,051/2,421 Sec#87/231 |
| Value | ||
| P/E | 2.44x | KR#105/2,421 Sec#4/231 |
| P/B | 0.34x | KR#423/2,421 Sec#15/231 |
| P/S | 0.45x | KR#841/2,421 Sec#34/231 |
| EV/EBITDA | 34.34x | KR#1,247/2,421 Sec#77/231 |
| FCF Yield | -0.32% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | 14.06% | KR#371/2,421 Sec#26/231 |
| ROA | 8.31% | KR#412/2,421 Sec#30/231 |
| Op. Margin | 3.04% | KR#1,248/2,421 Sec#89/231 |
| Revenue Growth | 4.23% | KR#1,244/2,421 Sec#124/231 |
| Earnings Growth | -20.66% | KR#933/2,421 Sec#58/231 |
| Financial Health | ||
| Debt Ratio | 69.23% | KR#1,210/2,421 Sec#147/231 |
| Total Debt | 75.57B KRW | KR#834/2,421 Sec#55/231 |
| FCF | -179.1M KRW | KR#1,233/2,421 Sec#93/231 |
| Cash | 1.12B KRW | KR#2,328/2,421 Sec#220/231 |
| Current Ratio | 0.52x | KR#2,129/2,421 Sec#205/231 |
| Net Debt/EBITDA | 19.64x | KR#1,369/2,421 Sec#98/231 |
| Dividend | ||
| Div. Yield | 3.77% | KR#464/2,421 Sec#18/231 |
| Div. Growth | 0.00% | KR—/2,421 Sec—/231 |
| Performance | ||
| 1Y Return | -34.00% | KR#1,681/2,421 Sec#133/231 |
| 1M Return | -0.25% | KR#1,265/2,421 Sec#96/231 |
| From 52W High | -34.77% | KR#694/2,421 Sec#46/231 |
| 1Y MDD | -42.47% | KR#677/2,421 Sec#50/231 |
| Trading | ||
| Volume | 10,322 shares | KR#1,900/2,421 Sec#184/231 |
| Trading Value | 40.7M KRW | KR#1,912/2,421 Sec#191/231 |
| Foreign Own. | 3.04% | KR#1,280/2,421 Sec#117/231 |
| Per Share | ||
| EPS | 1,613 KRW | KR#522/2,421 Sec#37/231 |
| BPS | 11,472 KRW | KR#900/2,421 Sec#62/231 |
Company Info
Jinyang Pharmaceutical, a mid-sized company, was established in 1971 for manufacturing and selling pharmaceuticals, converted to a corporation in 1978, and listed on KOSDAQ in 2000. It produces prescription and over-the-counter drugs, with a focus on the circulatory system segment, aiming for differentiation through new drug development from its generic-centric business structure. The company pursues substantial growth by strengthening marketing for its core circulatory products, investing in R&D, and developing new products. It is also preparing to launch new products through domestic and international patents and technology partnerships. Jinyang Pharmaceutical is headquartered in Seocho-gu, Seoul.